Changes and predictors for change to thiazolidinedione prescribing in UK primary care following the rosiglitazone safety warning

International Journal of Clinical Practice

Volumn 65, Issue 5, 2011, Pages 586-591

  Hall, G C ^a   Smith, H T ^b   Curtis, B ^b   McMahon, A D ^c  

^a Grimsdyke House   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

^c GLASGOW DENTAL HOSPITAL AND SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; INSULIN; MEGLITINIDE; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA;

ADULT; AGED; ARTICLE; DEMOGRAPHY; DISEASE COURSE; DISEASE DURATION; DRUG INFORMATION; DRUG SAFETY; DRUG SUBSTITUTION; FEMALE; HUMAN; INSULIN TREATMENT; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PRESCRIPTION; PRIMARY HEALTH CARE; PRIORITY JOURNAL; RISK FACTOR; SEASONAL VARIATION; SEX RATIO; TREATMENT DURATION; UNITED KINGDOM;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; DRUG SUBSTITUTION; DRUG TOXICITY; FAMILY PRACTICE; FEMALE; GREAT BRITAIN; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; RISK FACTORS; SAFETY-BASED DRUG WITHDRAWALS; THIAZOLIDINEDIONES;

EID: 79954496520     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2011.02648.x     Document Type: Article

References (20)

1. Nissen SE, Wolski K,. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-71. (Pubitemid 46919772)
2. McGuire DK,. Rosiglitazone and cardiovascular disease: an epidemiologist's perspective. Diab Vasc Dis Res 2007; 4: 77-9. (Pubitemid 47167488)
3. Tanne JH,. Study indicates diabetes drug linked to cardiovascular death. BMJ 2007; 334: 1073.
4. Surrey PCT,. Rosiglitazone and Cardiovascular Safety. Medicines Management Matters 2007. 2009. (accessed June 2008).
5. Doncaster PCT,. MHRA Statement on Cardiac Safety of Rosiglitazone. Doncaster Apothecary DONCASTER PCT PRESCRIBING NEWSLETTER 2007. (accessed June 2008).
6. Stewart KA, Natzke BM, Williams T, Granger E, Casscells SW, Croghan TW,. Temporal trends in anti-diabetes drug use in tricare following safety warnings in 2007 about rosiglitazone. Pharmacoepidemiol Drug Saf 2009; 18: 1048-52.
7. Starner CI, Schafer JA, Heaton AH, Gleason PP,. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events. J Manag Care Pharm 2008; 14: 523-31.
8. Shah BR, Juurlink DN, Austin PC, Mamdani MM,. New use of rosiglitazone decreased following publication of a meta-analysis suggesting harm. Diabet Med 2008; 25: 871-4.
9. George J, Hannah S, Lang CC,. Thiazolidinediones and the influence of media adverse reporting on prescribing attitudes in practice (TZD-IMPACT) study. Cardiovasc Ther 2009; 27: 83-8.
10. Nesto RW, Bell D, Bonow RO, et al., Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003; 108: 2941-8. (Pubitemid 37517824)
11. Kahn SE, Haffner SM, Heise MA, et al., Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-43. (Pubitemid 44903747)
12. Joint Formulary Committee. British National Formulary 55. March 2008. (accessed May 2008).
13. Harrell FE Jr, Lee KL, Califf RM, Pryor DB, Rosati RA,. Regression modelling strategies for improved prognostic prediction. Stat Med 1984; 3: 143-52. (Pubitemid 14052973)
14. Harrell FE Jr, Lee KL, Mark DB,. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-87. (Pubitemid 26072233)
15. Altman DG, Bland JM,. Diagnostic tests 3: receiver operating characteristic plots. BMJ 1994; 309: 188. (Pubitemid 24216486)
16. Surrey PCT,. Glitazones in the News Again! Medicine Management Matters 2007. (accessed August 2008).
17. Martin A,. Glitazones: Advice for Prescribers August 2007. 2007 (accessed December 2008).
18. Dollow S,. Increased Incidence of Fractures in Female Patients Who Received Long-Term Treatment with Avandia (rosiglitazone maleate). 2007 (accessed December 2008).
19. Swift M,. Important Safety Information Regarding Fractures with Pioglitazone. 2007 (accessed December 2008).
20. MHRA and CHMP. Rosiglitazone and Pioglitazone: Cardiovascular Safety and Fracture Risk. Drug Safety Update: 2007 (accessed December 2008).